$18.18
4.30%
NYSE, Oct 09, 04:10 pm EDT. Closed.
ISIN
US87911K1007
Symbol
HQL

Tekla Life Sciences Investors Stock price

$18.15
-2.19 10.77% 1M
+0.93 5.40% 6M
+1.37 8.16% YTD
+2.05 12.73% 1Y
+5.61 44.74% 3Y
-2.15 10.59% 5Y
-0.40 2.16% 10Y
+5.26 40.81% 20Y
NYSE, Closing price Fri, Oct 09 2026
+0.72 4.13%
ISIN
US87911K1007
Symbol
HQL

Is Tekla Life Sciences Investors a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
$532.2m
Enterprise Value
$532.2m
Net debt
$0.0
Cash
-
Shares outstanding
30.0m
Valuation
P/E
2.8
P/S | estimate
479.5 | -
EV/Sales | estimate
479.5 | -
EV/FCF | ex SBC
13.1 | -
P/B
1.0
Dividends
DPS
$1.74
Yield 1Y | 5Y
9.6% | 10.6%
Growth 1Y | 5Y
-4.4% | 0.6%
Payout 1Y | 3Y
63.6% | 73.6%
Increased
0 Years
Financials
Revenue | estimate
$1.1m | -
EBITDA
-
EBIT
$-4.8m
Net Income
$198.0m
Free Cash Flow | ex SBC
$40.6m | -
Growth
Revenue | estimate
-66.1% | -
EBITDA
-
EBIT
-79.2%
Net Income
1,750.0%
Free Cash Flow
208.6%
Margin
Gross
-419.8%
EBITDA
-
EBIT
-427.9%
Net
17,837.8%
Free Cash Flow | ex SBC
3,656.8% | -
Financial Health
Equity Ratio
99.8%
Return on Equity
16.7%
ROCE
-0.9%
ROIC
-
Debt/Equity
0.0
More
EPS
$6.6
FCF per Share
$1.4
Short interest
-
Employees
-
Rev per Employee
-

Financial data from Tekla Life Sciences Investors

Mar '26
+/-
%
1.11 1.11
66% 66%
100%
- Direct Costs 5.77 5.77
1% 1%
520%
-4.66 -4.66
81% 81%
-420%
- Selling and Administrative Expenses 0.02 0.02
100% 100%
2%
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -4.75 -4.75
79% 79%
-428%
Net Profit 198 198
1,750% 1,750%
17,838%

In millions USD.

Don't miss a Thing! We will send you all news about Tekla Life Sciences Investors directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tekla Life Sciences Investors Stock News

Neutral
PRNewsWire
●
5 months ago
PHILADELPHIA, May 11, 2026 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on May 29, 2026 to all shareholders of record as of May 21, 2026 (ex-dividend...

Company Profile

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

Head office United States
CEO Dan Omstead
Founded 1992
Website www.aberdeeninvestments.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today